|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Conjunctivitis, infectious |
|
Diarrhea, infectious |
|
Ulcer, corneal |
| |
|
|
SIDE EFFECTS:
|
|
Allergic reaction, such as skin rash, hives, or itching |
|
blurred vision |
|
corneal infiltrates |
|
corneal staining |
|
decreased vision |
|
epitheliopathy |
|
keratopathy |
|
dermatitis |
|
eye pain or irritation |
|
keratitis |
|
nausea |
|
Burning or other discomfort of the eye |
|
crusting or crystals in corner of eye |
|
Bad taste following instillation |
|
foreign body sensation |
|
hyperemia, conjunctival |
|
itching of eye |
|
Dryness of eye |
|
lid edema |
|
photophobia |
|
tearing of eye |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
|
|
ADULT DOSE:
|
|
Bacterial conjunctivitis-
Topical, to the conjunctiva, 1 drop in each eye every two hours, while patient is awake, for two days, then 1 drop every four hours, while patient is awake, for the next five days.
Corneal ulcers-
Topical, to the conjunctiva, 2 drops in the affected eye every fifteen minutes for six hours, then 2 drops every thirty minutes, while patient is awake, for the rest of day one; 2 drops every hour, while patient is awake, on day two; and 2 drops every four hours, while patient is awake, on days three through fourteen. If corneal re-epithelialization has not occurred after fourteen days of treatment, treatment may be continued.
Note: During the initial 24 to 48 hours, additional doses may be necessary during the night in some cases. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Bacterial conjunctivitis-
Infants and children up to 1 year of age: Safety and efficacy have not been established.
Children over 1 year of age: See Usual adult and adolescent dose.
Corneal ulcers-
In the U.S.-
Infants and children up to 1 year of age: Safety and efficacy have not been established.
Children over 1 year of age: See Usual adult and adolescent dose.
In Canada-
Infants and children up to 12 years of age: Safety and efficacy have not been established.
Children over 12 years of age: See Usual adult and adolescent dose. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|